BMI View: Significant regulatory changes in response to the illegal rebate scandal in South Korea will be
unlikely. The country already has tough laws in place, which can be leveraged to impose tough penalties on
Novartis and other firms practicing such sales tactics. ..."
BMI View: Policies in support of the local pharmaceutical sector in South Korea will be forthcoming. The
sector has the potential to serve as an alternative to electronic exports in driving economic growth, which
has been facing headwinds. Government support at this j ..."
BMI View: South Korea will remain an important market for innovative pharmaceutical firms in the Asia
Pacific. While the country's designation as a 'Watch List' country in PhRMA's 2016 submission highlights
concerns over the regulatory environment, this is an improvem ..."
BMI View: South Korea's biomedical research and development sector will continue to flourish in line with
growing investments by local drugmakers. Facilitating this commitment is the strong support provided by
the government as well as the opportunities to form drug d ..."
BMI View: The South Korean government will continue to enforce price pressures on pharmaceuticals as a
means to contain the escalating healthcare costs brought on by the country's ageing population. This is
particularly as other avenues - including shifting the health ..."
BMI View: The domestic pharmaceutical industry will continue to have conflicts with the South Korean
government over price controls. As a result of these price controls, growth of the pharmaceutical market
will be limited and firms need to expand overseas to sustain their busin ..."
BMI View: South Korea's pharmaceutical market will continue to grow in low-single digit terms due to the
government's aim to contain healthcare expenditure in general and pharmaceutical
costs in particular. Consequently, domestic companies will have to expand beyond S ..."
BMI View: South Korea continues to invest in pharmaceutical research and development (R&D). In one of
the latest developments in this area, the South Korea Health Ministry announced in July 2013 that it will
spend a total of KRW10trn (US$8.9bn) on projects to develop ..."
BMI View: The fourth quarter of 2012 brought positive revenue growth for large domestic
pharmaceutical firms in South Korea, the first positive result following many erratic price cuts that had
been instituted since 2011. We highlight a slow positive change in sentiment in the ..."
GBI Research’s new report, “South Korea Pharmaceutical Market Outlook 2013” provides in-depth analysis of the trends, issues and challenges facing the South Korean pharmaceutical market. The report also provides competitive benchmarking for the country’s leading pharmaceutical co ..."